drugset / Trial / NCT07520162

A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

NCT07520162

Phase 3 Recruiting 230 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.

Timeline

Start
2026-04-24
Primary completion
2028-03-01
Completion
2028-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tezepelumab Monoclonal antibody 210 mg Subcutaneous